Research and Markets: The Parkinsons Disease Market Is Set To Continue To Grow Over The Next 7 Years, Reaching Over $2.37 Billion In 2013, A 39% Increase From 2006 Levels
Posted on: Monday, 22 October 2007, 09:00 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c72211) has announced the addition of "Pipeline and Commercial Insight: Parkinsons Disease - Market to grow as first round of lifecycle management strategies" succeed to their offering.
Introduction
The PD market is set to continue to grow over the next 7 years, reaching over $2.37 billion in 2013, a 39% increase from 2006 levels. Combinations, reformulations, and indication expansions will drive the majority of this growth, with key brands expected to be Novartis/Orions Stalevo, GlaxoSmithKlines (GSKs) Requip Modutab, and UCB-Schwarzs Neupro.
Scope
Analysis of patient potential, unmet needs and clinical trial design in PD Overview of key marketed brands, late- and early-stage pipeline drugs, and cell/gene therapies. Indication- and country-specific sales volume and value forecasts to 2016 of marketed brands, generics, and key late-stage pipeline drugs. Identification of future market events that are expected to affect PD drug revenues.
Highlights
GSKs Requip Modutab will become the market leading PD brand in 2011. It will be intuitive for prescribers to believe that sustained activation of dopamine receptors with Requip Modutab could have a significant clinical benefit over pulsed agonism with standard drugs. New pipeline drugs will need to be innovative to compete in an increasingly crowded market. While this is evident in Eisais E2007, it is lacking in Merck-Serono/Newrons safinamide. Early studies with cell/gene therapies show great promise for significantly slowing the progression of the disease. However, these alternative approaches will not significantly impact the sales of pharmaceuticals over the forecast period 2007-2016.
Reasons to Purchase
Benchmark key late-stage PD compounds against current market leading brands. Assess country-specific (US, Japan, France, Germany, Italy, Spain and the UK) sales forecasts of key late-stage pipeline drugs and marketed brands. Understand unmet needs and opportunities in the PD market based on key opinion leader comments.
For more information, visit http://www.researchandmarkets.com/reports/c72211
Source: Datamonitor
Source: Business Wire
Related Articles
- Human Genome Reports Success Of Late-Stage Lupus Drug Trial
- Promising Alzheimer's Drug Approved for Late-Stage Trials
- Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
- Research and Markets: Opioid Antagonists Are the Most Prevalent Drug Class in Late-Stage Development for the Alcohol Dependence Pipeline Which Include Two Reformulations of Naltrexone
- Amgen Provides Update on Late-Stage and Early-Stage Pipeline at UBS Global Life Sciences Conference
- EpiCept Pain Drug to Enter Late-Stage Trials
- Avanir Pain Drug Successful in Late-Stage Trial
- Eurand Pancreas Drug Enters Second Late-Stage Trial
- Breast Cancer Clinical Drug, Derived From Botanical Extract, Could Treat Aggressive Late Stage Breast Cancer
- Swiss Firm Halts Plans for 2 Drugs Failed Late-Stage Tests Hurt Serono's Outlook
 |
 |
User Comments (0)
RSS Feeds